Anvi Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 06-07-2024
- Paid Up Capital ₹ 1.00 M
as on 06-07-2024
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2022
- Revenue 2.04%
(FY 2020)
- Profit -37.98%
(FY 2020)
- Ebitda 20.54%
(FY 2020)
- Net Worth 6.42%
(FY 2020)
- Total Assets 14.69%
(FY 2020)
About Anvi Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Rajashekaraiah Manjunatha, Kundan Gupta, Balasaheb Kakade, and One other member serve as directors at the Company.
- CIN/LLPIN
U24233MH2016PTC271597
- Company No.
271597
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jan 2016
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Anvi Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajashekaraiah Manjunatha  | Additional Director | 24-Feb-2016 | Current |
| Kundan Gupta | Additional Director | 24-Feb-2016 | Current |
| Balasaheb Kakade | Additional Director | 24-Feb-2016 | Current |
| Mahima Bhat | Additional Director | 23-Jan-2023 | Current |
Financial Performance of Anvi Pharmaceuticals.
Anvi Pharmaceuticals Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 2.04% increase. The company also saw a substantial fall in profitability, with a 37.98% decrease in profit. The company's net worth moved up by a moderate rise of 6.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anvi Pharmaceuticals?
In 2020, Anvi Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Lionelpi Consulting Private LimitedActive 2 years 6 monthsRajashekaraiah Manjunatha is a mutual person
Vedayur Bioscience Private LimitedActive 3 years 7 monthsRajashekaraiah Manjunatha is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Anvi Pharmaceuticals?
Unlock and access historical data on people associated with Anvi Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anvi Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anvi Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
